Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: JAMA Intern Med. 2014 Nov 1;174(11):1736–1745. doi: 10.1001/jamainternmed.2014.4052

Table 4.

Hair Analysis Results

Primary Drug
BI-B SAR MSO Total
Baseline 332/352 (94%) 313/338 (93%) 325/354 (92%) 970/1044 (93%)
Month 3 * 244/275 (89%) 265/280 (95%) 253/287 (88%) 762/842 (90%)
Month 6 244/282 (87%) 255/282 (90%) 257/294 (87%) 756/858 (88%)
Month 12 220/265 (83%) 222/268 (83%) 229/269 (85%) 671/802 (84%)
Any Drug
BI-B SAR MSO Total
Baseline 358/367 (98%) 334/343 (97%) 353/360 (98%) 1045/1070 (98%)
Month 3 263/274 (96%) 278/285 (98%) 266/282 (94%) 807/841 (96%)
Month 6 267/275 (97%) 276/282 (98%) 277/290 (96%) 820/847 (97%)
Month 12 241/260 (93%) 251/264 (95%) 256/268 (96%) 748/792 (94%)
*

Contrasts MSO vs., SAR and BI-B vs., SAR are significant, p = .022.